Inhaled siRNA therapy targeting the RAGE receptor successfully reached lung tissue and reduced the RAGE protein (sRAGE) by up to 90% in bronchoalveolar lavage fluid in a first-in-human clinical trial published in Nature Medicine. O’Carroll and colleagues, the experimental drug ARO-RAGE delivered via aerosol effectively intercepted the mRNA of the AGER gene responsible for producing the RAGE protein without altering human DNA.
What Is the RAGE Receptor and Why Target It?
The Receptor for Advanced Glycation End products, known as RAGE, acts as a critical amplifier of immune signals within alveolar lung cells. When activated, RAGE recruits immune cells that worsen tissue damage in conditions like asthma and chronic obstructive pulmonary disease (COPD). According to the study published in Nature Medicine, blocking this receptor provides a way to interrupt multiple inflammatory pathways simultaneously. However, researchers emphasize that RAGE does not operate in a vacuum; chronic respiratory diseases stem from a complex mix of genetics, environmental pollutants, cigarette smoke, and allergens.
How Inhaled siRNA Silences Pulmonary Inflammation
ARO-RAGE utilizes small interfering RNA (siRNA) to intercept messenger RNA (mRNA) from the AGER gene, which provides the biological instructions for building the RAGE protein. According to clinical trial data registered under ClinicalTrials.gov identifier NCT05276570, the aerosolized treatment binds to specific receptors on the pulmonary epithelium. This mechanism destroys the targeted mRNA temporarily, reducing protein synthesis without making permanent changes to the patient’s genetic code. Developer Arrowhead Pharmaceuticals engineered the delivery method to keep the drug concentrated inside the lungs rather than spreading through the systemic circulation.
Phase 1/2a Clinical Trial Results in Humans
The initial clinical evaluation enrolled 58 healthy volunteers and 19 patients with mild-to-moderate asthma to test safety and target engagement. According to findings published by O’Carroll et al. in Nature Medicine, a single inhaled dose of ARO-RAGE lowered soluble RAGE (sRAGE) protein levels by up to 77% in the blood after 29 days. In the fluid collected from bronchoalveolar lavage, the reduction reached approximately 90%. Trial monitors observed favorable safety profiles, noting no clinically significant changes in chest X-rays, systemic inflammation markers, or pulmonary function tests.
While the trial proved that inhaled siRNA successfully modifies biological targets in human airways, researchers caution that target engagement does not automatically equate to a clinical cure. According to the study authors, the Phase 1/2a trial lacked the size and duration required to measure improvements in daily symptoms such as coughing, wheezing, or asthma attacks. Evaluating whether molecular suppression translates into tangible relief for patients requires larger, longer-term trials compliant with global guidelines from the Global Initiative for Asthma (GINA) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD).
Related reading